SpecialtiesMedical specialties
How we see rheumatology billing.
Reviewed by the VisMed medical specialties billing team
Biologic infusions are the largest line on most rheumatology ledgers and the most fragile. Each drug on each plan has authorization criteria, step-therapy requirements, a site-of-care policy and an allowed rate. The practice buys the drug up front. If the authorization lapses, the units are wrong, the NDC is missing or the plan pays below cost, the practice has lost the price of the drug, not just the fee.
The clinic is complex chronic management: multi-system disease, immunosuppressants, frequent lab review. It supports higher E/M levels and, for many patients, care management. Injections and musculoskeletal ultrasound add procedure lines that need modifier and image-retention discipline.
VisMed builds a rheumatology account around the infusion chair: authorization as a case per patient per drug, reimbursement checked against acquisition, units and NDCs reconciled to the inventory, and re-authorization started before the approval expires.
Where rheumatology practices lose money
The patterns we find in the aging and denial history before anything else changes.
Authorization lapses mid-course
Approvals expire, dose changes need new approval, and plan changes at open enrollment reset everything. A dose given after the approval ended is not paid.Units, wastage and NDC errors
J-codes are billed by units that rarely match the vial. Wastage needs the right modifier and documentation, and many plans require the NDC. Errors are denials on high-dollar lines.Drugs paid below acquisition
Allowed rates vary by plan. Infusing on a plan that pays below cost is a loss per dose, repeated monthly.Site-of-care steering
Plans that mandate home or specialty-pharmacy supply deny office infusion after the fact if the policy was not checked.Complex visits and procedures undercoded
Immunosuppressant management is high-complexity decision-making, and injections with ultrasound guidance need separate lines and retained images.
What we do differently for rheumatology
Specialty-matched coders and a denials specialist, working inside your own system.
We run each infusion authorization as a case
Every patient on every drug has a case with approval dates, dose, criteria and re-authorization deadline, and we send the request before expiry.We compare reimbursement with cost per plan
We check allowed rates against your acquisition cost by drug and plan, so infusion decisions are made with the margin visible.We reconcile inventory monthly
Units billed, wastage documented and NDCs reported are reconciled against your drug inventory.We review leveling and capture procedures
Decision-making review of chronic visits, and templates that keep injections, guidance and the evaluation distinct.
What we bill
The procedure and code families your account team already works in.
Rheumatology billing, asked and answered.
What a physician-owner in this specialty asks on the first call.
How does VisMed keep infusion authorizations from lapsing?
Each patient-drug combination is a case with an expiry date. VisMed starts re-authorization ahead of expiry with the documentation the plan wants, and dose or plan changes trigger a new request before the next infusion.
Can VisMed tell us which drugs lose money on which plans?
VisMed compares each plan’s allowed rate for each drug with your acquisition cost and gives you the list. Where office infusion loses money, we route the drug to specialty pharmacy and you bill administration.
How does VisMed handle wastage?
Documented in the note, billed with the wastage modifier where the payer requires it, and reconciled against the vial sizes in inventory so units and wastage add up.
What about biosimilars?
Each has its own code and often a different rate and coverage position per plan. VisMed tracks them as separate drugs in the case system and flags when a plan prefers one over another.
What happens at open enrollment when patients change plans?
VisMed re-verifies every infusion patient in January, opens a new authorization case under the new plan before the first scheduled dose, and re-checks the allowed rate, because a plan change can turn a profitable drug into a loss overnight.
Also in medical specialties
Cardiology
Diagnostics, device checks and cath-lab professional fees.
Endocrinology
CGM, infusion and chronic-condition management codes.
Gastroenterology
Endoscopy, ASC splits and screening-vs-diagnostic rules.
Hepatology
Infusions, specialty drugs and prior authorization.
Nephrology
Dialysis MCP, monthly capitation and transplant follow-up.
Pulmonology
PFTs, sleep crossover and DME orders.
Neurology
EEG/EMG, infusion and long-visit E/M.
Oncology
Chemotherapy administration, drugs and NDC reporting.
Hematology
Infusion and lab-linked visits.
Immunology & allergy
Testing panels and immunotherapy series.
Infectious disease
Inpatient rounds, long-term therapy and telehealth.
Dermatology
Lesion coding, pathology and cosmetic separation.
Pain management
Injections, ablations and strict authorization trails.
Psychiatry
Med-management with therapy add-ons, parity rules.
All specialties
The full list, in six groups
See where your rheumatology practice is losing money. Free.
Six months of aging and denials, read by people who bill your specialty every day — quantified as monthly leakage with a recovery estimate. Yours to keep.
or write directly hello@vis.med